Lonza signs five-year collaboration deal with VC firm Bioqube to speed up portfolio companies’ development and manufacturing

The offering will accelerate timelines for the development and manufacturing of molecules and disruptive technologies

CDMO Lonza has signed a deal with Bioqube Ventures for the future development and manufacture of biologics and small molecules for the European venture capital firm’s portfolio companies.

Under the terms of the five-year services agreement, Lonza will support Bioqube Ventures during the due diligence of candidate biotechs and provide a tailored offering of advice and services to its portfolio companies.

In a statement, the companies said the offering would help to accelerates timelines while mitigating risks of the development and manufacturing of molecules ranging from monoclonal antibodies, complex proteins, and small molecules to antibody-drug conjugates.

They said the holistic approach to drug substance and drug product development and manufacturing across various platforms significantly simplifies the supply chain, reduces process complexity, and allows for a shortened development timelines.

Debora Dumont, Co-founder and Managing Partner, Bioqube Ventures, said the company’s portfolio companies now had “the opportunity to leverage Lonza's expertise and its global network, supporting our hands-on approach in building new and successful ventures.”